Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
Ovaviu fɔ di tin dɛn we dɛn dɔn lan
We di pipul dɛn de ol kwik kwik wan na di mɔdan sosayti, sik dɛn we gɛt fɔ du wit di pankrias wok, lɛk tayp 2 dayabitis ɛn di we aw dɛn nɔ ebul fɔ bia wit glukɔs, dɔn de bɔku mɔ ɛn mɔ. Pancragen, we na wan tetrapeptide, dɔn gɛt bɔku atɛnshɔn insay di las ia dɛn we dɛn de du risach bɔt pankrias wɛlbɔdi biznɛs.
Figure 1 Di kεmikכl strכkchכ fכ Pankragen.
Di Rεgεlεtכri Efεkt dεm we Pankragen gεt pan Pankrεas εndokrin Fכnshכn
Glukɔs Rɛgyuleshɔn
insay stכdi dεm pan ol rεsכs mכnkey dεm, dεn fכnshכn se afta dεn gi wan standad dכz fכ glukכs, di 'disappearance' rεt fכ glukכs bin lכw pan ol animal dεm kכmpεr wit yכng animal dεm, we sho se di glukכs kliarεns kapasiti dכn dכn. כltu, we dεn gi ol rεsכs mכnkey dεm Pancragen via intramכskular injεkshכn (50 μg/animal/de fכ 10 dez), di 'disappearance' rεt fכ glukכs bin sכmtεm inkrεs. dis sho se Pancragen kin mek di bכdi in mεtabolik kεpasiti fכ glukכs bכku, we de mek di blכd glukכs kכmכt fast fast εn fכ mεnten di blכd glukכs lεvεl stebul. dis mεkanism fכ akshכn de riliyt to Pankragen in rεguleshכn fכ pankrεas εndokrin sεl dεm, as i kin mek insulin sekreshכn כ εnhans insulin sεnsitiviti, we de mek di pεrifεral tisu כptek εn yutilizeshכn fכ glukכs εn lכs di blכd glukכs lεvεl.
Rεgulεshכn fכ insulin εn C-pεptida lεvεl dεm
di stכdi sho bak se afta dεn gi glukכs, di pik lεvεl dεm fכ insulin εn C-pεptida (5 εn 15 minit afta dεn injεkt glukכs) bin hכy pan ol animal dεm pas yכng animal dεm. Dis de sho se di we aw insulin de kɔmɔt pan animal dɛn we dɔn ol nɔmal. di yus fכ Pancragen de rεstכr nכmal plasma insulin εn C-pεptida kεnεtiks. di C-pεptida de sekret insay ikwal molar amoun wit insulin, εn chenj dεm na in lεvεl dεm de sho di wok we pankrεas β-sεl dεm de du. pankragen de mek di nכmal insulin εn C-pεptida lεvεl dεm kam bak, we de sho se in positifu rεgεdyushכn ifekt pan pankrεas β-sεl fכnshכn, we de εp fכ mεnten nכmal insulin sekreshכn ritm dεm. dis na imכtant fכ mek di blכd glukכs lεvεl stebul εn fכ mek sכh se di glukכs mεtabolism nכmal na di bכdi.
Pankragen ɛn Improvmɛnt fɔ Impayr Glukɔs Tolɛreshɔn
Rizult fɔ di Ɛkspiriɛns fɔ Animal
Nayn klinik hεlty ol uman rεsכs mכnkey dεm we ol 20–25 ia dεn yuz as stכdi sכbjεkt dεm. pan dɛn 5 pan dɛn bin injɛkt wit Pancragen (0.05 mg/animal/de, intramuscular injection, fɔ 10 dez), ɛn 4 dɛn bin administret di kɔmɔn yus antidiabetic drɔg glimepiride (4 mg/animal/de, ɔral administreshɔn, fɔ 10 dez). Pancragen ɛn glimepiride ɔl tu bin ridyus di basal blɔd glukɔs lɛvɛl na di ol mɔnki dɛn. pankragen nכ de nכmכ de lכs di glukכs na di bכdi, bכt i de mek di insulin εn C-pεptida lεvεl dεm kam bak to nכmal, we de sho se i gεt rεstכretiv ifekt pan di impεriכs glukכs tכlerans insay animal dεm we ol. pankragen de sho yunik advantej dεm fכ impruv di impεriכs glukכs tכlerans, as i nכ de כnli ridyus di blכd glukכs lεvεl bכt mכr imכtant i de adrεs di rut kכz bay we i de rεgεl pankrεas εndokrin fכnshכn, we de εnhans di bכdi in ebul fכ tכlerεt glukכs.
Pɔtɛnɛshɛl klinik implikashɔn dɛn
If yu nɔ ebul fɔ tek di glukɔs fayn fayn wan na di stej we pɔsin kin gɛt bifo i gɛt tayp 2 dayabitis, ɛn if dɛn nɔ adrɛs am, i kin izi fɔ mek i gɛt dayabitis. di ebul we pankragen ebul fכ impruv glukoz tכlerans na animal dεm we ol de gi nyu tin dεm fכ di prεvεnshכn εn tritmεnt fכ tayp 2 dayabεtis. Fɔ pipul dɛm we de na di impaired glucose tolerance stej, patikyular di ol pipul dɛm, Pancragen kin bi sef ɛn ifektiv intavɛnshɔn fɔ delay ɔr prɛvɛnt di prɔgrɛs to dayabitis.
Di Promotin Efεkt we Pankragen Gεt pan Pankrεas Sεl Difrεns
Rεgulεshכn fכ di εksprεshכn fכ di sεl difrεns mak dεm
rεsכch dεn sho se as di pankrεas sεl dεm de ol, di εksprεshכn fכ difrεns mak dεm de dכn. כltu, Pancragen kin stimulate di εksprεshכn fכ pankrεas difrεns fכktכ dεm (lεk PDX1 εn PTFLA) εn aylet sεl mak dεm (PDX1, PAX6, PAX4, FOXA2, εn NKX2.2) insay כl tu di 'young' εn 'aged' kכltכr dεm. dis difrεns fכ difrεns fכ di nכmal difrεns εn fכnshכnal mεntenans fכ di pankrεas sεl dεm. PDX1 na di kכl rεgεlεt fכ di pankrεas divεlכpmεnt εn pankrεas β-sεl fכnshכn, εn in inkrεs εksprεshכn de εp fכ promuot di difrεns εn fכnshכnal rεkכvεshכn fכ pankrεas β-sεl dεm. pankragen de promuot di difrεns fכ di pankrεas sεl dεm insay nכmal fכnshכnal sεl dεm bay we i de upregulate di εksprεshכn fכ dεn difrεns mak dεm ya.
Difrɛns Mɛkanism ɛn Ɛlth Implikashɔn
pankragen de indyuz di difrεns bitwin pankrεas aylet εn acinar sεl dεm, wan prכsεs we na wan pan di kכl mεkanism dεm we de כndalayn in anti-dayabεtik εn anti-inflammatory ifekt dεm. bay we i de mek di sεl dεm difrεns, Pankragen de εp fכ mεnten di strכkchכral εn fכnshכnal integriti fכ di pankrεas tisu, i de εnhans di pankrεas in abiliti fכ rεgεl di blכd glukכs lεvεl, εn i de ridyus inflammatory damej to pankrεas tisu. dis prכmoshכn fכ pankrεas sεl difrεns de gi wan pכtεnshal tεrapi tכgεt fכ trit pankrεas-rεlatεd sik dεm lεk dayabεtis εn pankrεas.
Aplikeshɔn Pɔtɛnshɔnal fɔ Pankragen insay di Ol pipul dɛn
Adrɛs pan di pankrɛas disfɔkshɔn we gɛt fɔ du wit di ej
Insay di mɔdan sosayti dɛmografik strɔkchɔ, di big big inkris na di ol pipul dɛm na wan pan di praymar rizin dɛm fɔ di rising nɔmba fɔ di pasɛnt dɛm we gɛt tayp 2 dayabitis ɛn di impεriɔs glukɔs tolɛreshɔn. di positifu ifekt dεm we Pancragen gεt pan pankrεas εndokrin fכnshכn insay ol pipul dεm we nכ de fכ mכtalman praymat dεm de sho se in brayt aplikεshכn pכtεnshal insay di ol pipul dεm. i kin rigul εn impruv di ej-rεlatεd pankrεas disfכnkshכn na di ol pipul dεm, εp dεm fכ mεnten nכmal blכd glukכs lεvεl εn pankrεas fכnshכn.
Dɔn
fכ sכmari, Pancragen dכn sho mכlti fכs fayn fayn ifekt dεm na di fild fכ pankrεas hεlth. i kin rεgεl di pankrεas εndokrin fכnshכn, i kin impruv di blכd glukכs lεvεl εn di sekreshכn patεn fכ insulin εn C-pεptida fayn fayn wan; i gεt gud rεstכraytiv ifekt pan impεriכs glukכs tכlerεns, we de gi nyu stratεji fכ prεvεnshכn εn tritmεnt fכ tayp 2 dayabεtis; bay we i de mek di pankrias sεl difrεns, i de mεnten di stεbiliti fכ di pankrεas tisu strכkchכ εn fכnshכn, we de ple imכtant rol fכ trit sik dεm lεk dayabεtis εn pankrεas.
Sos dɛn we dɛn pul
[1] Goncharova ND, Ivanova LG, Oganyan T. E., ɛn ɔda pipul dɛn. [Kכrekshכn fכ impεriכs glukכs tכlerεns yuz tεtrapεptida (Pancragen) insay ol uman rεsכs mכnkey dεm][J]. Advans in Jεrכntכlכji, 2015,28(3):579-585.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Rεtriv&db=pubmed&dopt=Abstrakt&list_uids=28509500&kwεri_hl=1
[2] Goncharova ND, Ivanova LG, Oganian T É, ɛn ɔda pipul dɛn. [Impεkt fכ tεtrapεptida pankrεgen pan εndokrin fכnshכn fכ di pankrεas insay ol mכnkey dεm][J]. Advans in Jεrכntכlכji, 2014,27(4):662-667.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Rεtriv&db=pubmed&dopt=Abstrakt&list_uids=25946840&kwεri_hl=1
[3] Khavinson V, Durnova AO, Polyakova V. O., ɛn ɔda pipul dɛn. ifekt dεm we pankragen de gi pan di difrεns fכ di pankrεas sεl dεm we dεn de ol[J]. Bulletin of Ekspirimɛnt Bayoloji ɛn Mɛdisin, 2013,154(4):501-504.DOI:10.1007/s10517-013-1987-6.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
